Obstetrics & Gynecology Doctors in Blacksburg, VA Accepting Medicare

7 Obstetrics & Gynecology doctors found. Showing 1 - 7

Laurie J Hudgins, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 826 Davis St, Blacksburg, VA 24060 Phone: 540-951-1550    Fax: 540-951-7427

Erica Madlock Royal, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 826 Davis St, Blacksburg, VA 24060 Phone: 540-443-0500

Dr. Tamera L Howell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1997 S Main St, Blacksburg, VA 24060 Phone: 540-961-1058

Dr. Cathleen G Callahan, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2265 Kraft Dr, Blacksburg, VA 24060 Phone: 540-231-0915    Fax: 540-231-5367

Margarita Angela Abrams, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 825 Davis St, Ste C, Blacksburg, VA 24060 Phone: 540-251-0980    Fax: 540-251-0985

Nikola Alexander Letham, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 826 Davis St, Blacksburg, VA 24060 Phone: 540-443-0500    Fax: 540-553-0526

Dr. George T Zolovick, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 826 Davis St, Blacksburg, VA 24060 Phone: 540-951-1550    Fax: 540-951-7427

News Archive

National clinical trial to test potential vaccine against SARS-CoV-2

UC San Diego Health and the Altman Clinical and Translational Research Institute, part of UC San Diego School of Medicine, will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Mindfulness meditation can reduce stress hormone

Focusing on the present rather than letting the mind drift may help to lower levels of the stress hormone cortisol, suggests new research from the Shamatha Project at the University of California, Davis.

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

EMA validates InterMune's pirfenidone MAA for IPF

InterMune, Inc. today announced that the company's Marketing Authorization Application (MAA), submitted on March 2 seeking approval of pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, was validated by the European Medicines Agency (EMA). Validation of the MAA by the EMA indicates that the application is complete and that the review process will begin on March 24. The proposed trade name for pirfenidone in both the United States and Europe is Esbriet®.

Emerson Ecologics announces exclusive distribution of EcoNugenics' BreastDefend dietary supplement

Emerson Ecologics, LLC announces an exclusive distribution to healthcare practitioners of BreastDefend™, EcoNugenics' newest product. BreastDefend is a professional dietary supplement formulated specifically to promote and maintain breast cellular health. EcoNugenics chose to distribute this product solely through Emerson Ecologics for the initial product launch because of Emerson's 16,000 practitioner customer base, as well as their strong quality assurance program.

Read more Medical News

› Verified 6 days ago